There is an error in [Table 2](#pone.0188991.t001){ref-type="table"}. Two cells in the row corresponding to patients under 18 years of age at diagnosis were incorrectly shifted to the left. The value "6" should appear in the "*n*" column and "16 (3.1--28.4)" should be listed in the "Mean months (95% CI)" column. The publisher apologizes for this error. Please see the corrected [Table 2](#pone.0188991.t001){ref-type="table"} here.
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###### Kaplan-Meier survival analyses for overall survival of all patients with osteosarcoma and for overall survival and post metastases overall survival of patients with osteosarcoma presented with metastases at diagnosis or developed metastases during treatment/follow-up.

![](pone.0188991.t001){#pone.0188991.t001g}

  Characteristics                                              All patients with osteosarcoma (*n* = 53)   Patients with metastatic osteosarcoma (*n* = 33)                                                                                                                                             
  ------------------------------------------------------------ ------------------------------------------- -------------------------------------------------- ---------------------------------------------- ---- ----------------- -------------------------------------------- ---- ----------------- --------------------------------------------
  Age at diagnosis[^a^](#t001fn002){ref-type="table-fn"}                                                                                                                                                                                                                                                
      ≤ 18 yrs                                                 42                                          56 (40.9--70.9)                                    0.013[\*](#t001fn006){ref-type="table-fn"}     27   34 (23.9--43.3)   0.062                                        27   24 (15.8--32.4)   0.011[\*](#t001fn006){ref-type="table-fn"}
      \> 18 yrs                                                11                                          19 (8.4--28.9)                                                                                    6    16 (3.1--28.4)                                                 6    9 (3.3--15.2)     
  Gender                                                                                                                                                                                                                                                                                                
      Male                                                     36                                          51 (34.7--66.8)                                    0.780                                          27   32 (21.6--42.0)   0.485                                        27   23 (14.0--31.4)   0.389
      Female                                                   17                                          45 (24.2--66.2)                                                                                   6    24 (16.1--31.8)                                                6    16 (8.9--23.5)    
  Site of tumor                                                                                                                                                                                                                                                                                         
      Femur                                                    31                                          58 (39.2--77.2)                                    0.326                                          16   32 (20.5--43.7)   0.661                                        16   26 (14.7--37.6)   0.208
      Tibia or fibula or others                                22                                          40 (24.2--55.0)                                                                                   17   28 (16.5--39.6)                                                17   16 (9.0--23.6)    
  Histologic subtype                                                                                                                                                                                                                                                                                    
      Non osteoblastic                                         25                                          62 (41.1--81.9)                                    0.102                                          16   36 (24.0--47.9)   0.140                                        16   22 (15.3--28.7)   0.451
      Osteoblastic                                             28                                          37 (22.6--51.7)                                                                                   17   24 (13.8--33.4)                                                17   19 (8.9--29.0)    
  Primary tumor volume[^b^](#t001fn003){ref-type="table-fn"}                                                                                                                                                                                                                                            
      \< 500 mL                                                26                                          69 (49.2--89.3)                                    0.002[\*](#t001fn006){ref-type="table-fn"}     12   43 (26.4--59.6)   0.074                                        12   28 (12.6--43.8)   0.374
      ≥ 500 mL                                                 19                                          24 (15.2--33.0)                                                                                   14   24 (14.4--32.6)                                                14   20 (11.9--27.1)   
  Presence of metastasis at diagnosis                                                                                                                                                                                                                                                                   
      No                                                       34                                          65 (47.1--82.8)                                    0.0003[\*](#t001fn006){ref-type="table-fn"}    14   41 (28.5--52.8)   0.037[\*](#t001fn006){ref-type="table-fn"}   14   18 (12.3--24.4)   0.882
      Yes                                                      19                                          22 (12.5--30.7)                                                                                   19   22 (12.5--30.7)                                                19   21 (12.1--30.4)   
  Time to metastases                                                                                                                                                                                                                                                                                    
      \> 12 months                                                                                                                                                                                           8    53 (37.1--69.4)   0.028[\*](#t001fn006){ref-type="table-fn"}   8    21 (11.9--29.4)   0.688
      ≤ 12 months                                                                                                                                                                                            6    25 (16.6--33.1)                                                6    16 (7.1--25.0)    
      At diagnosis                                                                                                                                                                                           19   22 (12.5--30.7)                                                19   21 (12.1--30.4)   
  Site of metastases                                                                                                                                                                                                                                                                                    
      Lung only                                                                                                                                                                                              25   34 (24.0--44.7)   0.050                                        25   25 (15.6--33.6)   0.019[\*](#t001fn006){ref-type="table-fn"}
      Bone or multiple organs                                                                                                                                                                                8    18 (8.5--26.5)                                                 8    12 (6.7--16.4)    
  Histologic response[^c^](#t001fn004){ref-type="table-fn"}                                                                                                                                                                                                                                             
      Good                                                     13                                          87 (59.2--114.7)                                   0.024[\*](#t001fn006){ref-type="table-fn"}     5    37 (17.0--57.5)   0.379                                        5    25 (7.5--42.3)    0.419
      Poor                                                     22                                          41 (27.4--53.8)                                                                                   16   29 (19.6--38.8)                                                16   20 (14.1--25.2)   
  Chemotherapy                                                                                                                                                                                                                                                                                          
      Both neoadjuvant & adjuvant                              34                                          65 (48.0--81.8)                                    0.00003[\*](#t001fn006){ref-type="table-fn"}   21   34 (25.0--43.8)   0.133                                        21   23 (16.6--29.0)   0.183
      Either neoadjuvant or adjuvant, or no chemotherapy       19                                          20 (9.4--30.0)                                                                                    12   22 (8.3--35.1)                                                 12   17 (3.8--29.9)    
  Total FAK expression                                                                                                                                                                                                                                                                                  
      Non-over                                                 5                                           66 (21.1--109.9)                                   0.449                                          2    29 (17.5--40.9)   0.958                                        2    21 (15.2--26.6)   0.962
      Over                                                     48                                          45 (32.6--57.0)                                                                                   31   30 (21.3--39.4)                                                31   21 (13.8--29.0)   
  pFAK-Y397 expression                                                                                                                                                                                                                                                                                  
      Non-over                                                 20                                          60 (37.5--82.5)                                    0.258                                          12   41 (23.2--58.1)   0.044[\*](#t001fn006){ref-type="table-fn"}   12   32 (14.9--48.6)   0.029[\*](#t001fn006){ref-type="table-fn"}
      Over                                                     33                                          40 (26.2--54.6)                                                                                   21   24 (16.4--32.1)                                                21   15 (11.5--19.4)   
  Total FAK/pFAK-Y397 co-expression                                                                                                                                                                                                                                                                     
      Non-over/non-over                                        5                                           66 (21.1--109.9)                                   0.502                                          2    29 (17.5--40.9)   0.098                                        2    21 (15.2--26.6)   0.071
      Over/non-over                                            15                                          49 (29.0--68.3)                                                                                   10   43 (22.3--63.6)                                                10   34 (14.0--53.8)   
      Over/over                                                33                                          40 (26.2--54.6)                                                                                   21   24 (16.4--32.1)                                                21   15 (11.5--19.4)   

CI, confidence interval; OS, overall survival; PMOS, post metastases overall survival.

^a^ Mean value of age at diagnosis: patients with metastatic osteosarcoma, ≤ 21 yrs vs \> 21 yrs.

^b^ All patients with osteosarcoma, evaluated only in 45 patients (8 patients, no preoperative MRI); patients with metastatic osteosarcoma, evaluated only in 26 patients (7 patients, no preoperative MRI).

^c^ All patients with osteosarcoma, evaluated only in 35 patients who received neoadjuvant chemotherapy (5 patients, no neoadjuvant chemotherapy; 5 patients, no chemotherapy; 8 patients, no data); patients with metastases, evaluated only in 21 patients who received neoadjuvant chemotherapy (5 patients, no neoadjuvant chemotherapy; 5 patients, no chemotherapy; 2 patients, no data).

^d^ Log rank (Mantel-Cox) test.

\* Statistically significant.
